It has also been approved for use in conjunction with nivolumab to treat PD-L1 positive metastatic NSCLC, MSI-H, or dMMR metastatic CRC, and other cancers (Arias-Pinilla and Modjtahedi 2021). Here, CD274 is linked to cancer.